Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
December 08, 2023 09:15 ET
|
Novartis Pharma AG
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in...
ELISpot and FluoroSpot Assay Market is Expected to Reach $421 million | MarketsandMarkets.
December 04, 2023 07:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Dec. 04, 2023 (GLOBE NEWSWIRE) -- ELISpot and FluoroSpot Assay market in terms of revenue was estimated to be worth $292 million in 2023 and is poised to reach $421 million by 2028, growing...
Cell Culture Consumables Market revenue to reach USD 400 Billion by 2036, says Research Nester
November 21, 2023 07:30 ET
|
Research Nester
New York, Nov. 21, 2023 (GLOBE NEWSWIRE) -- The global cell culture consumables market size is projected to grow at a CAGR of over ~23% from 2024 to 2036. The market is expected to garner a revenue...
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 03, 2023 06:00 ET
|
Turnstone Biologics Corp.
Posters showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for solid tumors.
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
November 01, 2023 16:10 ET
|
Prelude Therapeutics, Inc.
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023 16:05 ET
|
Prelude Therapeutics, Inc.; AbCellera
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber
October 30, 2023 06:00 ET
|
Turnstone Biologics Corp.
Internationally recognized cancer immunotherapy thought leader, Dr. Weber, will help guide Turnstone’s continued advancement of its Selected TIL therapies
Global Preclinical Imaging Market Set to Reach $5.95 Billion by 2030, Driven by Research and Development Investments
October 18, 2023 09:53 ET
|
Research and Markets
Dublin, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The "Preclinical Imaging Market Size, Share & Trends Analysis Report By Product (CT Imaging, Services, Ultrasound Imaging), By Application (Research and...
Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 28, 2023 06:00 ET
|
Turnstone Biologics Corp.
Turnstone Biologics to present preclinical data for its Selected TILs at SITC's 38th Annual Meeting.
Global NSCLC Market Dynamics and Innovations: Striving to Transform Lung Cancer Treatment
September 05, 2023 09:51 ET
|
Research and Markets
Dublin, Sept. 05, 2023 (GLOBE NEWSWIRE) -- The "Non-Small Cell Lung Cancer Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company...